EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.

Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.

A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.

Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.

US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.

September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.

EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.